Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: Clinical significance of in vitro and in vivo findings

British Journal of Pharmacology

Volumn 165, Issue 2, 2012, Pages 289-312

  O'Brien, Fionn E ^a   Dinan, Timothy G ^a,b   Griffin, Brendan T ^b   Cryan, John F ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

ABC drug efflux transporter; ABCB1; antidepressant; blood brain barrier; MDR1; P glycoprotein; treatment resistant depression

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYCLOSPORIN; DESIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID; GLYCOPROTEIN P; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NORFLUOXETINE; NORSERTRALINE; NORTRIPTYLINE; PAROXETINE; PROTRIPTYLINE; QUINIDINE; RISPERIDONE; SERTRALINE; TRAZODONE; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; VERAPAMIL;

BLOOD BRAIN BARRIER; DEPRESSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG INTERACTION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TREATMENT FAILURE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STRESS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DEPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; P-GLYCOPROTEIN; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 83755205460     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01557.x     Document Type: Review

References (172)

1. Abbott NJ, Ronnback L, Hansson E, (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: 41-53. (Pubitemid 41828930)
2. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ, (2010). Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13-25.
3. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo RP, et al,. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323: 1718-1722.
4. Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet C, et al,. (2010). Pericytes regulate the blood-brain barrier. Nature 468: 557-561.
5. Avdeef A, (2011). How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood-brain barrier permeability? Eur J Pharm Sci. doi: 10.1016/j.ejps.2011.1004.1001.
6. Ballabh P, Braun A, Nedergaard M, (2004). The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16: 1-13. (Pubitemid 38569790)
7. Bauer B, Hartz AMS, Fricker G, Miller DS, (2004). Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 66: 413-419. (Pubitemid 39329239)
8. Bauer B, Hartz AMS, Miller DS, (2007). Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol Pharmacol 71: 667-675. (Pubitemid 46294078)
9. Bauer B, Hartz AMS, Lucking JR, Yang XD, Pollack GM, Miller DS, (2008). Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GST pi, at the blood-brain barrier. J Cereb Blood Flow Metab 28: 1222-1234. (Pubitemid 351733346)
10. Begley DJ, (2004). ABC transporters and the blood-brain barrier. Curr Pharm Des 10: 1295-1312. (Pubitemid 38559749)
11. Benet LZ, (2009). The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6: 1631-1643.
12. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP, (2000). Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23: 428-438.
13. Brightman MW, Reese TS, (1969). Junctions between intimately apposed cell membranes in vertebrate brain. J Cell Biol 40: 648-677.
14. Carroll BJ, (1982a). Clinical-applications of the dexamethasone suppression test for endogenous-depression. Pharmacopsychiatria 15: 19-24.
15. Carroll BJ, (1982b). The dexamethasone suppression test for melancholia. Br J Psychiat 140: 292-304. (Pubitemid 12184534)
16. Carroll BJ, Cassidy F, Naftolowitz D, Tatham NE, Wilson WH, Iranmanesh A, et al,. (2007). Pathophysiology of hypercortisolism in depression. Acta Psychiatr Scand 115: 90-103. (Pubitemid 46114844)
17. Cascorbi I, (2006). Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112: 457-473. (Pubitemid 44486412)
18. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, et al,. (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69: 169-174. (Pubitemid 32225417)
19. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, et al,. (2007). Replicating genotype-phenotype associations. Nature 447: 655-660. (Pubitemid 46889722)
20. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, et al,. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373: 746-758.
21. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM, (2004). Expression, up-regulation, and transport activity of the multidrug-resistance protein ABCG2 at the mouse blood-brain barrier. Cancer Res 64: 3296-3301. (Pubitemid 38581436)
22. Clarke G, O'Mahony SM, Cryan JF, Dinan TG, (2009). Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter? Hum Psychopharmacol 24: 217-223.
23. Colabufo NA, Berardi F, Cantore M, Contino M, Inglese C, Niso M, et al,. (2010). Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. J Med Chem 53: 1883-1897.
24. Cordoncardo C, O'Brien JP, Casals D, Rittmangrauer L, Biedler JL, Melamed MR, et al,. (1989). Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial-cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86: 695-698. (Pubitemid 19037807)
25. Cryan JF, Holmes A, (2005). The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4: 775-790. (Pubitemid 43090498)
26. Cryan JF, Leonard BE, (eds) (2010). Depression: From Psychopathology to Pharmacotherapy. Karger: Basel.
27. Dauchy S, Dutheil F, Weaver RJ, Chassoux F, Daumas-Duport C, Couraud PO, et al,. (2008). ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 107: 1518-1528.
28. De Luca V, Mundo E, Trakalo J, Wong GWH, Kennedy JL, (2003). Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. Pharmacogenomics J 3: 297-299. (Pubitemid 37428194)
29. Devault A, Gros P, (1990). Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol Cell Biol 10: 1652-1663.
30. Dinan TG, (2009). Inflammatory markers in depression. Curr Opin Psychiatry 22: 32-36.
31. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, et al,. (2005). The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 33: 165-174. (Pubitemid 40023528)
32. Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottée L, et al,. (2009). Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 37: 1528-1538.
33. Ebinger M, Uhr M, (2006). ABC drug transporter at the blood-brain barrier-effects on drug metabolism and drug response. Eur Arch Psychiatry Clin Neurosci 256: 294-298. (Pubitemid 44285053)
34. Eckford PDW, Sharom FJ, (2009). ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109: 2989-3011.
35. Ehret MJ, Levin GA, Narasimhan M, Rathinavelu A, (2007). Venlafaxine induces P-glycoprotein in human Caco-2 cells. Hum Psychopharmacol 22: 49-53. (Pubitemid 46178778)
36. Ejsing TB, Linnet K, (2005). Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier. Hum Psychopharmacol 20: 149-153. (Pubitemid 40372491)
37. Ejsing TB, Hasselstrom J, Linnet K, (2006). The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabol Drug Interact 21: 139-162. (Pubitemid 43971436)
38. El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P, (2004). Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmaccokinetics of selected substrates. J Pharm Pharmacol 56: 967-975. (Pubitemid 39140051)
39. Eyal S, Hsiao P, Unadkat JD, (2009). Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123: 80-104.
40. Fava M, (2003). Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53: 649-659. (Pubitemid 39658481)
41. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, et al,. (2008). In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36: 268-275. (Pubitemid 351185738)
42. Fukui N, Suzuki Y, Sawamura K, Sugai T, Watanabe J, Inoue Y, et al,. (2007). Dose-dependent effects of the 3435 C >T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients. Ther Drug Monit 29: 185-189. (Pubitemid 46716184)
43. Gex-Fabry M, Eap CB, Oneda B, Gervasoni N, Aubry JM, Bondolfi G, et al,. (2008). CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Ther Drug Monit 30: 474-482.
44. Ghersi-Egea JF, Leninger-Muller B, Suleman G, Siest G, Minn A, (1994). Localization of drug-metabolizing enzyme-activities to blood-brain interfaces and circumventricular organs. J Neurochem 62: 1089-1096. (Pubitemid 24064523)
45. Gottesman MM, Fojo T, Bates SE, (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58. (Pubitemid 37328807)
46. Grauer MT, Uhr M, (2004). P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline. J Psychopharmacol 18: 66-74. (Pubitemid 38623096)
47. Halbreich U, Asnis GM, Shindledecker R, Zumoff B, Nathan RS, (1985). Cortisol secretion in endogenous-depression.1. basal plasma-levels. Arch Gen Psychiatry 42: 904-908. (Pubitemid 16248516)
48. Hawkins BT, Davis TP, (2005). The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57: 173-185. (Pubitemid 41043883)
49. Hayashi Y, Nomura M, Yamagishi SI, Harada SI, Yamashita J, Yamamoto H, (1997). Induction of various blood-brain barrier properties in non-neural endothelial cells by close apposition to co-cultured astrocytes. Glia 19: 13-26. (Pubitemid 27050446)
50. Hermann DM, Bassetti CL, (2007). Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends Pharmacol Sci 28: 128-134. (Pubitemid 46283592)
51. Herr AS, Tsolakidou AF, Yassouridis A, Holsboer F, Rein T, (2003). Antidepressants differentially influence the transcriptional activity of the glucocorticoid receptor in vitro. Neuroendocrinology 78: 12-22. (Pubitemid 36921030)
52. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al,. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473-3478. (Pubitemid 30183327)
53. Holsboer F, (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
54. Holthoewer D, Hiemke C, Schmitt U, (2010). Induction of drug transporters alters disposition of risperidone-a study in mice. Pharmaceutics 2: 258-274.
55. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A, (2000). Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther 295: 1276-1283.
56. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, Ripke S, et al,. (2009). A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66: 966-975.
57. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K, (2001). Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11: 175-184. (Pubitemid 32216128)
58. Jaffrezou JP, Chen G, Duran GE, Muller C, Bordier C, Laurent G, et al,. (1995). Inhibition of lysosomal acid sphingomyelinase by agents which reverse multidrug-resistance. Biochim Biophys Acta 1266: 1-8.
59. Janzer RC, Raff MC, (1987). Astrocytes induce blood-brain barrier properties in endothelial cells. Nature 325: 253-257. (Pubitemid 17049884)
60. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, et al,. (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72: 584-594. (Pubitemid 36237730)
61. Juliano RL, Ling V, (1976). Surface glycoprotein modulating drug permeability in chinese-hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
62. Julio-Pieper M, Dinan TG, (2010). The hypothalamic-pituitary-adrenal axis in depression. In:, Cryan JF, Leonard BE, (eds). Depression: From Psychopathology to Pharmacotherapy. Karger Press: Basel, pp. 20-31.
63. Kalvass JC, Pollack GM, (2007). Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res 24: 265-276. (Pubitemid 46072186)
64. Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, et al,. (2009). Imaging the function of p-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 86: 368-377.
65. Karlsson L, Schmitt U, Josefsson M, Carlsson B, Ahlner J, Bengtsson F, et al,. (2010). Blood-brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. Eur Neuropsychopharmacol 20: 632-640.
66. Karlsson L, Hiemke C, Carlsson B, Josefsson M, Ahlner J, Bengtsson F, et al,. (2011). Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology (Berl) 215: 367-377.
67. Karssen AM, Meijer OC, van der Sandt ICJ, Lucassen PJ, de Lange ECM, de Boer AG, et al,. (2001). Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology 142: 2686-2694. (Pubitemid 32473126)
68. Karssen AM, Meijer OC, van der Sandt ICJ, De Boer AG, De Lange ECM, De Kloet ER, (2002). The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol 175: 251-260. (Pubitemid 35276604)
69. Karssen AM, Meijer OC, Pons D, De Kloet ER, (2004). Localization of mRNA expression of P-glycoprotein at the blood-brain barrier and in the hippocampus. Ann N Y Acad Sci 1032: 308-311. (Pubitemid 40298503)
70. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, et al,. (2008). ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol 32: 398-404. (Pubitemid 351178955)
71. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al,. (2001). Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70: 189-199. (Pubitemid 32777772)
72. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al,. (2007). A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528. (Pubitemid 46175758)
73. Kirschbaum KM, Henken S, Hiemke C, Schmitt U, (2008). Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res 188: 298-303.
74. de Klerk OL, Willemsen ATM, Roosink M, Bartels AL, Hendrikse NH, Bosker FJ, et al,. (2009). Locally increased P-glycoprotein function in major depression: a PET study with [C-11]verapamil as a probe for P-glycoprotein function in the blood-brain barrier. Int J Neuropsychopharmacol 12: 895-904.
75. de Klerk OL, Bosker FJ, Willemsen AT, Van Waarde A, Visser AK, de Jager T, et al,. (2010). Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats. J Psychopharmacol 24: 1237-1242.
76. Kraft P, (2008). Curses-winner's and otherwise-in genetic epidemiology. Epidemiology 19: 649-651.
77. Kunzel HE, Binder EB, Nickel T, Ising M, Fuchs B, Majer M, et al,. (2003). Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 28: 2169-2178. (Pubitemid 37468184)
78. Kuteykin-Teplyakov K, Luna-Tortos C, Ambroziak K, Loscher W, (2010). Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br J Pharmacol 160: 1453-1463.
79. Laika B, Leucht S, Steimer W, (2006). ABCB1 (P-Glycoprotein/MDR1) Gene G2677T/A Sequence Variation (Polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem 52: 893-895. (Pubitemid 43673271)
80. Lazarowski A, Caltana L, Merelli A, Rubio MD, Ramos AJ, Brusco A, (2007). Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? J Neurol Sci 258: 84-92. (Pubitemid 46876736)
81. Lee SH, Lee MS, Lee JH, Kim SW, Kang RH, Choi MJ, et al,. (2010). MRP1 polymorphisms associated with citalopram response in patients with major depression. J Clin Psychopharmacol 30: 116-125.
82. Lin JH, (2007). Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab 3: 81-92. (Pubitemid 47307456)
83. Lin KM, Chiu YF, Tsai IJ, Chen CH, Shen WW, Liu SC, et al,. (2011). ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment. Pharmacogenet Genomics 21: 163-170.
84. Liptrott NJ, Penny M, Bray PG, Sathish J, Khoo SH, Back DJ, et al,. (2009). The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC. Br J Pharmacol 156: 497-508.
85. Litman T, Druley TE, Stein WD, Bates SE, (2001). From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959. (Pubitemid 32652819)
86. Loscher W, Potschka H, (2005). Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6: 591-602. (Pubitemid 41059334)
87. Maines LW, Antonetti DA, Wolpert EB, Smith CD, (2005). Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 49: 610-617. (Pubitemid 41208282)
88. Mason BL, Pariante CM, Thomas SA, (2008). A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice. Endocrinology 149: 5244-5253.
89. Mason BL, Pariante CM, Jamel S, Thomas SA, (2010). Central nervous system (CNS) delivery of glucocorticoids is fine-tuned by saturable transporters at the blood-CNS barriers and nonbarrier regions. Endocrinology 151: 5294-5305.
90. Mason BL, Thomas SA, Lightman SL, Pariante CM, (2011). Desipramine treatment has minimal effects on the brain accumulation of glucocorticoids in P-gp-deficient and wild-type mice. Psychoneuroendocrinology. doi: 10.1016/j.psyneuen.2011.1003.1008.
91. Meijer OC, de Lange ECM, Breimer DD, de Boer AG, Workel JO, de Kloet ER, (1998). Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology 139: 1789-1793. (Pubitemid 28513838)
92. Merry S, Hamilton TG, Flanigan P, Freshney RI, Kaye SB, (1991). Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine. Eur J Cancer 27: 31-34.
93. Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M, Lovric M, (2008). MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 32: 1439-1444.
94. Miller DS, (2010). Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 31: 246-254.
95. Muller MB, Keck ME, Binder EB, Kresse AE, Hagemeyer TP, Landgraf R, et al,. (2003). ABCB1 (MDR1)-Type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology 28: 1991-1999. (Pubitemid 37412108)
96. Narang VS, Fraga C, Kumar N, Shen J, Throm S, Stewart CF, et al,. (2008). Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am J Physiol Cell Physiol 295: C440-C450. (Pubitemid 352755780)
97. Neuwelt E, Abbott N, Abrey L, Banks WA, Blakley B, Davis T, et al,. (2008). Strategies to advance translational research into brain barriers. Lancet Neurol 7: 84-96. (Pubitemid 350258701)
98. Neuwelt EA, Bauer B, Fahlke C, Fricker G, Iadecola C, Janigro D, et al,. (2011). Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci 12: 169-182.
99. Nies AT, (2007). The role of membrane transporters in drug delivery to brain tumors. Cancer Lett 254: 11-29. (Pubitemid 47058801)
100. Nikisch G, Eap CB, Baumann P, (2008). Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 58: 344-347.
101. Pardridge WM, (2005). The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2: 3-14. (Pubitemid 40128022)
102. Pardridge WM, (2007). Blood-brain barrier delivery. Drug Discov Today 12: 54-61. (Pubitemid 46014479)
103. Pariante CM, (2008). The role of multi-drug resistance p-glycoprotein in glucocorticoid function: studies in animals and relevance in humans. Eur J Pharmacol 583: 263-271.
104. Pariante CM, Lightman SL, (2008). The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31: 464-468.
105. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH, (1997). Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 52: 571-581. (Pubitemid 27443978)
106. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH, et al,. (2001). Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol 134: 1335-1343. (Pubitemid 33097265)
107. Pariante CM, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin RW, (2003a). The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology 28: 1553-1561. (Pubitemid 41070855)
108. Pariante CM, Kim RB, Makoff A, Kerwin RW, (2003b). Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. Br J Pharmacol 139: 1111-1118. (Pubitemid 36920673)
109. Pariante CM, Thomas SA, Lovestone S, Makoff A, Kerwin RW, (2004). Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology 29: 423-447. (Pubitemid 38121601)
110. Pauwels EKJ, Erba P, Mariani G, Gomes CMF, (2007). Multidrug resistance in cancer: its mechanism and its modulation. Drug News Perspect 20: 371-377. (Pubitemid 350219069)
111. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP, (2010). Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 67: 1110-1113.
112. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, et al,. (2008). Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR D sample. PLoS ONE 3: e1872.
113. Peters EJ, Reus V, Hamilton SP, (2009). The ABCB1 transporter gene and antidepressant response. F1000 Biol Rep 1: 23.
114. Philip NS, Carpenter LL, Tyrka AR, Price LH, (2010). Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother 11: 709-722.
115. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, et al,. (2001). Rational use of in vitro p-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299: 620-628. (Pubitemid 32979675)
116. Reese TS, Karnovsky MJ, (1967). Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34: 207-217.
117. von Richter O, Glavinas H, Krajcsi P, Liehner S, Siewert B, Zech K, (2009). A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol 379: 11-26.
118. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA, (2002). A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2: 191-196. (Pubitemid 34982226)
119. Rochat B, Baumann P, Audus KL, (1999). Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res 831: 229-236. (Pubitemid 29336205)
120. Romsicki Y, Sharom FJ, (1999). The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 38: 6887-6896.
121. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al,. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am J Psychiatry 163: 1905-1917. (Pubitemid 44807782)
122. Sakurai A, Onishi Y, Hirano H, Seigneuret M, Obanayama K, Kim G, et al,. (2007). Quantitative structure-activity relationship analysis and molecular dynamics simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry 46: 7678-7693. (Pubitemid 47016053)
123. Salama NN, Yang ZP, Bui T, Ho RJY, (2006). MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 95: 2293-2308. (Pubitemid 44568538)
124. Sarginson JE, Lazzeroni LC, Ryan HS, Ershoff BD, Schatzberg AF, Murphy GM, (2010). ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 20: 467-475.
125. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA, (1992). Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267: 4854-4858.
126. Schiepers OJG, Wichers MC, Maes M, (2005). Cytokines and major depression. Prog Neuropsychopharmacol 29: 201-217. (Pubitemid 40202906)
127. Schinkel AH, (1999). P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36: 179-194. (Pubitemid 29121971)
128. Schinkel AH, Smit JJM, Vantellingen O, Beijnen JH, Wagenaar E, Vandeemter L, et al,. (1994). Disruption of the mouse Mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain-barrier and to increased sensitivity to drugs. Cell 77: 491-502. (Pubitemid 24153990)
129. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P, (1995). Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-1705.
130. Schinkel AH, Mayer U, Wagenaar E, Mol CAAM, vanDeemter L, Smit JJM, et al,. (1997). Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 94: 4028-4033. (Pubitemid 27180493)
131. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J, (2003). Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46: 1716-1725. (Pubitemid 36444224)
132. Shapiro AB, Ling V, (1997). Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein. Eur J Biochem 250: 122-129. (Pubitemid 27504591)
133. Sharom FJ, (2008). ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9: 105-127. (Pubitemid 351560534)
134. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al,. (2003). Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348: 1442-1448. (Pubitemid 36407173)
135. Spudich A, Kilic E, Xing HY, Kilic U, Rentsch KM, Wunderli-Allenspach H, et al,. (2006). Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci 9: 487-488.
136. Stein U, Walther W, Wunderlich V, (1994). Point mutations in the Mdr1 promoter of human osteosarcomas are associated with in-vitro responsiveness to multidrug-resistance relevant drugs. Eur J Cancer 30A: 1541-1545. (Pubitemid 24343018)
137. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ, (2001). P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol 41: 708-714. (Pubitemid 32612433)
138. Syvanen S, Hammarlund-Udenaes M, (2010). Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. Curr Top Med Chem 10: 1799-1809.
139. Szabo D, Szabo G Jr, Ocsovszki I, Aszalos A, Molnar J, (1999). Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139: 115-119. (Pubitemid 29222032)
140. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234. (Pubitemid 43336035)
141. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC, (1989). Immunohistochemical localization in normal-tissues of different epitopes in the multidrug transport protein P170-evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37: 159-164. (Pubitemid 19039163)
142. Thiel CM, Muller CP, Huston JP, Schwarting RK, (1999). High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments. Neuroscience 93: 243-251. (Pubitemid 29290704)
143. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al,. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40. (Pubitemid 43050100)
144. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, et al,. (1992). Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267: 24248-24252.
145. Uhr M, Grauer MT, (2003). abcblab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 37: 179-185. (Pubitemid 36313270)
146. Uhr M, Steckler T, Yassouridis A, Holsboer F, (2000). Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22: 380-387. (Pubitemid 30105766)
147. Uhr M, Holsboer F, Muller MB, (2002). Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol 14: 753-759.
148. Uhr M, Grauer MT, Holsboer F, (2003). Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54: 840-846. (Pubitemid 37205136)
149. Uhr M, Namendorf C, Grauer MT, Rosenhagen M, Ebinger M, (2004). P-glycoprotein is a factor in the uptake of dextromethorphan, but not of melperone, into the mouse brain: evidence for an overlap in substrate specificity between P-gp and CYP2D6. J Psychopharmacol 18: 509-515. (Pubitemid 39665119)
150. Uhr M, Grauer MT, Yassouridis A, Ebinger M, (2007). Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. J Psychiatr Res 41: 179-188. (Pubitemid 44708204)
151. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, et al,. (2008). Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 57: 203-209.
152. Urquhart BL, Kim RB, (2009). Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65: 1063-1070.
153. Vankalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, et al,. (1993). Cortisol is transported by the multidrug resistance gene-product p-glycoprotein. Br J Cancer 67: 284-289. (Pubitemid 23049551)
154. Varga A, Nugel H, Baehr R, Marx U, Hever A, Nacsa J, et al,. (1996). Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res 16: 209-211. (Pubitemid 26128468)
155. Volk HA, Burkhardt K, Potschka H, Chen J, Becker A, Löscher W, (2004). Neuronal expression of the drug efflux transporter P-glycoprotein in the rat hippocampus after limbic seizures. Neuroscience 123: 751-759. (Pubitemid 38045412)
156. Wacher VJ, Wu CY, Benet LZ, (1995). Overlapping substrate specificities and tissue distribution of cytochrome-P450 3a and P-Glycoprotein-implications for drug-delivery and activity in cancer-chemotherapy. Mol Carcinog 13: 129-134.
157. Wang JS, DeVane CL, Gibson BB, Donovan JL, Markowitz JL, Zhu HJ, (2006a). Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology 183: 490-499. (Pubitemid 41721151)
158. Wang JS, Zhu HJ, Marokowitz JS, Donovan JL, DeVane CL, (2006b). Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 187: 415-423. (Pubitemid 44200513)
159. Wang JS, Zhu HJ, Gibson BB, Markowitz JS, Donovan JL, DeVane CL, (2008). Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull 31: 231-234. (Pubitemid 351198395)
160. Weber CC, Kressmann S, Ott M, Fricker G, Müller WE, (2005). Inhibition of P-glycoprotein function by several antidepressants may not contribute to clinical efficacy. Pharmacopsychiatry 38: 293-300. (Pubitemid 41815686)
161. Weber CC, Eckert GP, Muller WE, (2006). Effects of antidepressants on the brain/plasma distribution of corticosterone. Neuropsychopharmacology 31: 2443-2448. (Pubitemid 44607062)
162. Weiss J, Dormann G, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE, (2003). Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305: 197-204. (Pubitemid 36373851)
163. Wolburg H, Lippoldt A, (2002). Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 38: 323-337. (Pubitemid 36398254)
164. Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P, (2009). Brain endothelial cells and the glio-vascular complex. Cell Tissue Res 335: 75-96.
165. Yamazaki M, Neway WE, Ohe T, Chen IW, Rowe JF, Hochman JH, et al,. (2001). In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther 296: 723-735. (Pubitemid 32187340)
166. Yasui-Furukori N, Saito M, Niioka T, Inoue Y, Sato Y, Kaneko S, (2007). Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Ther Drug Monit 29: 45-48. (Pubitemid 46279875)
167. Yau JLW, Noble J, Thomas S, Kerwin R, Morgan PE, Lightman S, et al,. (2007). The antidepressant desipramine requires the ABCB1 (Mdr1)-Type p-glycoprotein to upregulate the glucocorticoid receptor in mice. Neuropsychopharmacology 32: 2520-2529. (Pubitemid 350126842)
168. Yu CH, Kastin AJ, Tu H, Waters S, Pan WH, (2007). TNF activates P-glycoprotein in cerebral microvascular endothelial cells. Cell Physiol Biochem 20: 853-858. (Pubitemid 350059728)
169. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM, (2006). Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 3: 62-69. (Pubitemid 43331752)
170. Zhou SF, (2008). Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832.
171. Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL, (2007). Risperidone and paliperidone inhibit P-glycoprotein activity in vitro. Neuropsychopharmacology 32: 757-764. (Pubitemid 46426181)
172. Zlokovic BV, (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201.